Akron Biotech is part of the Advanced Regenerative Manufacturing Institute (ARMI) consortium to develop next-generation manufacturing processes and technologies for cells, tissues and organs. The ARMI will receive nearly $300 million in public-private investment from leading manufacturers, universities, nonprofit organizations and the federal government to develop scalable manufacturing processes for engineered tissues and organs.
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
StemBioSys Partners with VWR for U.S. and Canadian Distribution
SAN ANTONIO – StemBioSys Inc. announced today that it has entered into an agreement with VWR (NASDAQ: VWR) to distribute and market StemBioSys products.
VWR, the leading global independent provider of product and service solutions to laboratory and production facilities, will be the exclusive distributor for StemBioSys in both the United States and Canada. [Read more…]
Cord Blood Associations Form in the U.S., Brazil, and Worldwide
Cord Blood Associations first appeared with the formation of a cord blood association in Brazil in 2013. Shortly thereafter, the Cord Blood Association (CBA) formed in the U.S. in December of 2014. As the cord blood industry expands, the question becomes, what role with these cord blood associations play in supporting industry growth, collaboration, and education? [Read more…]
MD Anderson and NIH to Fund Clinical Trial Combining 2 Mesoblast Technologies
On December 6th, MD Anderson Cancer Center and NIH announced that they will be funding a clinical trial that will combine two Mesoblast technologies:
- Mesenchymal Precursor Cell (MPC)-based expansion
- Ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients
The purpose of the trial is to provide clinical data to indicate whether these technologies can interact synergistically to promote faster cord blood HSC engraftment for bone marrow transplant patients. [Read more…]
Precious Cells Group is First Employer Worldwide to Bank Stem Cells for Employees
First Ever Employer to Store Lifesaving Stem Cells for Employees
Edinburgh, UK, December 7, 2016 – Precious Cells is offering their employees the ultimate employee benefit unlike anything ever seen before. They will cryogenically store employees’ and their loved ones’ stem cells, for free. This means they can be used in treatment for life threatening conditions today, tomorrow and in the future. [Read more…]
- « Previous Page
- 1
- …
- 137
- 138
- 139
- 140
- 141
- …
- 145
- Next Page »